Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Eli Lilly & Co.    LLY   US5324571083

ELI LILLY & CO.

 (LLY)

21
 SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisionsForum 
Quotes 5-day view   Delayed Quote. Delayed Nyse
05/20/2013 05/21/2013 05/22/2013 05/23/2013 05/24/2013 Date
55.02(c) 55.14(c) 54.92(c) 54.74(c) 54.14(c) Last
4 242 518 4 221 928 4 570 047 3 952 981 4 875 704 Volume
-1.57% +0.22% -0.40% -0.33% -1.10% Change
More quotes
Company
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - neurology (33.5%): primarily drugs used in treating depression and schizophrenia; - endocrinology (30.1%): products for treating osteoporosis, diabetes, and growth... 
Sector
Pharmaceuticals - Diversified
Calendar
06/01 | 09:00amPresentation
Surperformance© rating of Eli Lilly & Co.
Trading Rating : Investor Rating :
More about the company
Chart ELI LILLY & CO.
Duration : Period :
Eli Lilly & Co. Technical Analysis Chart | LLY | US5324571083 | 4-Traders
Full-screen chart
Financials ($)
Sales 2013 22 750 M
EBIT 2013 5 271 M
Net income 2013 4 441 M
Debt 2013 918 M
Yield 2013 3,61%
Sales 2014 19 623 M
EBIT 2014 3 690 M
Net income 2014 2 958 M
Finance 2014 1 800 M
Yield 2014 3,61%
PER 2013 13,05
PER 2014 19,98
EV / Sales 2013 2,72x
EV / Sales 2014 3,02x
Capitalization 60 992 M
More Financials
Latest news on ELI LILLY & CO.
3d agoDJPfizer To Spin Off Remaining Zoetis Stake in Exchange Offer
5d ago ELI LILLY & CO.: From Research Labs to Doctors' Offices, Health Care Providers ..
05/15 Amazon gets help to lure big business to the cloud
05/14 ELI LILLY & CO.: Lilly Oncology to Release New Pipeline Data at ASCO 2013
05/14DJELI LILLY & CO.: Lilly CEO Recovering From Surgery for Dilated Aorta
05/14 ELI LILLY & CO.: Lilly Provides Update on CEO Dr. John Lechleiter
05/14 ELI LILLY & CO.: ex-dividend day
05/10 Drugmakers face more scrutiny of discordant U.S. prices
05/10DJELI LILLY & CO.: Eli Lilly Ends Development of Lymphoma Drug Enzastaurin; Misse..
05/10 ELI LILLY & CO.: Lilly Announces Enzastaurin Phase III Study Did Not Meet Prima..
05/06DJLilly CEO to Have Artery Surgery, Seen Returning by Fall
05/06DJLilly CEO to Have Artery Surgery, Seen Returning By Fall
More news
4-Traders Strategies on ELI LILLY & CO. 
2012Trend support as stepping stone
2012Trading opportunity
More Strategies
Forum ELI LILLY & CO.
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Technical analysis
Income Statement Evolution
Eli Lilly _ Co. : Income Statement Evolution
More Financials
EPS Revisions
Eli Lilly _ Co. : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF
Copyright © 2013 Surperformance. All rights reserved.